Carregant...
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsatisfactory. Many factors affect the outcome of a...
Guardat en:
| Publicat a: | Exp Hematol Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7923338/ https://ncbi.nlm.nih.gov/pubmed/33653420 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-021-00211-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|